Advice
Following a full submission
plerixafor (Mozobil) is accepted for use within NHSScotland in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.
Significantly more patients treated with plerixafor than with placebo achieved their target collection of CD 34+ cells required for autologous stem cell transplantation with subsequent sustained engraftment.
Download detailed advice96KB (PDF)
Medicine details
- Medicine name:
- plerixafor (Mozobil)
- SMC ID:
- 594/09
- Indication:
Combined with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection & subsequent autologous transplantation in patients with lymphoma and multiple myeloma
- Pharmaceutical company
- Genzyme Therapeutics Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 18 January 2010